Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Completed · Phase 3 · Has a placebo group

Conditions studied: Type2 Diabetes Mellitus

In brief

The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).

Key facts

Study ID
NCT03259789
Run by
Theracos
People needed
351
Starts
2017-11-28
Expected to finish
2019-01-23
Last updated by the study team
2021-07-07

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.